/
AMLX
$18.70+$0.91 (+5.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.0B
111M shares
52-week range
$5.97 – $18.75
100% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$0.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $650.0K | $0 | $22.2M | $380.8M | $87.4M | $0 |
| Cost of revenue | $11.9M | $24.6M | $0 | $3.0M | $25.4M | $42.2M | $525.0K |
| Gross profit | −$10.5M | −$23.9M | $0 | $19.2M | $355.3M | $45.2M | −$525.0K |
| Gross margin | -734.4% | -3683.7% | — | 86.5% | 93.3% | 51.8% | — |
| R&D | $11.9M | $24.6M | $44.0M | $93.5M | $128.2M | $104.1M | $90.4M |
| Operating income | −$13.6M | −$39.0M | −$82.7M | −$201.3M | $38.8M | −$314.7M | −$153.3M |
| EBITDA | $1.1M | −$39.0M | −$87.9M | −$197.1M | $55.4M | −$291.0M | −$144.2M |
| Net income | −$14.8M | −$42.3M | −$87.9M | −$198.4M | $49.3M | −$301.7M | −$144.7M |
| Net margin | -1039.0% | -6504.6% | — | -892.4% | 12.9% | -345.4% | — |
| EPS (diluted) | -0.26 | -0.79 | -1.52 | -2.98 | 0.70 | -4.43 | -1.53 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $80625 | $-1.41 | $-1.60–$-1.28 | 7 |
| 2027 | $45M | $-1.26 | $-1.69–$-0.89 | 6 |
| 2028 | $150M | $-0.62 | $-0.85–$0.25 | 6 |
| 2029 | $321M | $0.60 | $0.27–$0.93 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.30
Price
$18.70
Implied downside
-88%
Peer comparison
Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
www.amylyx.com- Employees
- 136
- IPO / List date
- Jan 7, 2022
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds AMLX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 192,500 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AMLX yet.
